Previous studies have shown that pretargeting protocols, using cancer-targeting fusion proteins, composed of 4 anti-CD20 single chain Fv (scFv) fragments and streptavidin (scFv 4 -SAv), followed by a biotinylated dendrimeric N-acetyl-galactosamine blood clearing agent (CA), 1, then a radiolabeled DOTA-biotin derivative (a mono-biotin), 3a, can provide effective therapy for lymphoma xenografts in mouse models. A shortcoming in this pretargeting system is that endogenous biotin may affect its efficacy in patients. To circumvent this potential problem, we investigated a pretargeting system that employs anti-CD20 scFv 4 -SAv mutant fusion proteins with radioiodinated bis-biotin derivatives. With that combination of reagents good localization of the radiolabel to lymphoma tumor xenografts was obtained in the presence of endogenous biotin. However, the blood clearance reagents employed in the studies were ineffective, resulting in abnormally high levels of radioactivity in other tissues. Thus, in the present investigation a bisbiotin-tri-galactose blood clearance reagent, 2, was designed, synthesized and evaluated in vivo. Additionally, another DOTA-biotin derivative (a bis-biotin), 4a, was designed and synthesized, such that radiometals (e.g. 111 
INTRODUCTION
Radioimmunotherapy (RIT3) employing radiolabeled anti-CD20 monoclonal antibodies (MAb) has proven to be efficacious as a treatment for patients with B-cell lymphomas (1) . While it seems likely that changes being evaluated in the current RIT treatment regimens will increase efficacy and/or decrease toxicity (2) (3) (4) , newer approaches to RIT, such as cancer "pretargeting" (5-7), may provide more significant improvements in the treatment of lymphoma. One of the pretargeting approaches being investigated uses monoclonal antibody-streptavidin (MAb-SAv) conjugates (8) (9) (10) , or related scFv 4 -SAv fusion proteins, in protocols where they are administered in an initial step, followed in subsequent steps by administration of a blood clearance agent, then a biotin derivative labeled with a therapeutic radionuclide. In preclinical investigations, it has been conclusively shown that pretargeting protocols in mouse models using MAb-SAv conjugates, or fusion proteins, reactive with CD20 (11) , or other lymphoma cell surface antigens (12, 13) , either alone or in combinations (14) , provides a more efficacious therapy than obtained with conventional RIT.
Although the MAb-SAv/radiolabeled biotin pretargeting approach benefits from the very high affinity of the biotin-SAv binding pair, a potential limitation in the approach is the fact that patient serum contains significant amounts of biotin (15) . Based on animal studies (16) , it is possible that endogenous biotin in patients blood can bind with administered MAb-SAv conjugates or fusion proteins to block the binding of subsequently administered blood clearance and radiolabeled biotin derivatives. To circumvent this problem, new MAb-SAv/ biotin binding pairs were designed and prepared. Site-directed mutations of the biotinbinding pocket in streptavidin (SAv) were performed to prepare SAv mutants that have decreased binding with biotin (17) . Subsequently, those SAv mutants were used to prepare scFv 4 -SAv mutant fusion proteins (18) . It was hypothesized that the decrease in biotin binding in the SAv mutants could be off-set by using bis-biotin derivatives, which would have increased binding due to dual binding with a single SAv molecule (19) and an avidity effect (20) . Therefore, a series of bis-biotin derivatives were synthesized and their binding with SAv mutants was assessed. Importantly, it was demonstrated that the bis-biotin derivatives could bind with the SAv mutants in the presence of biotin (21) . Later pretargeting studies demonstrated that tumor xenografts could be effectively targeted using scFv 4 -SAv mutant fusion proteins, a blood clearance agent, and a radioiodinated bis-biotin derivative, even when the mice were placed on a normal (biotin-containing) diet (22) . While the studies successfully demonstrated that a MAb-SAv/biotin-based pretargeting approach targeted tumors in the presence of endogenous biotin, the concentrations of radioactivity in normal tissues were much higher than those obtained in other pretargeting studies. The higher normal tissue concentrations appeared to be caused by a lack of efficient blood clearance when using either of the two blood clearing agents studied. Those agents included; [1] a monobiotin-hexadecyl-N-acetylgalactose derivative, 1, (Figure 1 ) and [2] a galactosylated and bis-biotinylated human serum albumin derivative (22) . 3 Abbreviations: ASOR, asialoorosomucoid protein; CA, blood clearance agent; CDI, carbonyldiimidazole; DCC, N,N'-dicyclohexylcarbodiimide; DOTA, 1,4,7,10-tetraazacyclododecane tetraacetic acid; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; FP, fusion protein; HOBT, 1-hydroxybenztriazole ; MAb, monoclonal antibody; PEG, polyethylene glycol; Ra/Ni, Raney-Nickel; RIP, relative inhibitory power; RIT, radioimmunotherapy; RB, radiolabeled biotin; SAv, streptavidin; scFv, single chain fusion of light and heavy chains in variable region of MAb; TCDI, thiocarbonyldiimidazole; TFA, trifluoroacetic acid; TFP-OTFA, 2,3,5,6-tetrafluorophenyl-O-trifluoroacetate; WT, wild-type (native) protein sequence
In the current studies, two new reagents, 2 and 4a (Figure 1 ), were synthesized for use in pretargeting protocols with scFv4-SAv mutant fusion proteins. A new biotin-containing blood clearance agent, 2, was designed and synthesized to evaluate the hypothesis that the unacceptably high concentrations of a radioiodinated bis-biotin derivative in normal tissues previously obtained was due to ineffective blood clearance of the antibody-SAv mutant fusion protein. Additionally, a bis-biotin derivative containing the metal chelation moiety DOTA, 4a was designed and synthesized due to our interest in using radiometals, such as Indium-111 ( 111 In) and Yttrium-90 ( 90 Y) in pretargeting protocols. The bis-biotin-DOTA derivative, 4a, was designed to be similar to the bis-biotiniodobenzoyl derivative previously shown to bind selectively with SAv mutants in the presence of biotin (21) . In addition to syntheses of the new reagents, studies were conducted in mice to demonstrate that the new reagents functioned as designed. A study was conducted in mice to compare the blood clearance of a scFv 4 -SAv mutant fusion in the presence of endogenous biotin when the clearing agents 1 and 2 were employed. Another study was conducted to evaluate whether 111 In-labeled 4a, [ 111 In]4b, could successfully target tumors in athymic mice bearing Ramos lymphoma. In that study, an anti-CD20 scFv 4 -SAv mutant fusion protein was administered, followed by blood clearance with 2, then administration of an 111 
EXPERIMENTAL PROCEDURES General
Chemicals purchased from commercial sources were analytical grade or better, and were used without further purification. Di-tert-butyl-dicarbonate, 2,2'-(ethylenedioxy)bis(ethylamine), nitromethanetrispropionic acid, acetobromo-α-D-galactose (2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide), 3-iodopropionic acid, 1,1'-carbonyldiimidazole (CDI), 1,1'-thiocarbonyldiimidazole (TCDI), Amberlite IR120 (hydrogen form), and most other chemicals were obtained from Sigma-Aldrich (Milwaukee, WI). L-aspartic acid α-t-butyl ester, 10, was obtained from Novabiochem (AMD Biosciences, Inc., San Diego, CA). D-biotin, 9, N-Boc-trioxatridecanediamine, 16, and N-(phthalimido)amino-dPEG 4 -acid, 19, were gifts from Quanta BioDesign, Powell, OH; aminobenzyl-DOTA (S-2-(4-Aminobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid), 31, was obtained from Macrocyclics, Inc. (Dallas, TX). Biotin-sarcosineaminobenzyl-DOTA, 3a, was prepared as previously described (23) [currently available from Macrocyclics, Inc, Dallas, TX]. 2,3,5,6-Tetrafluorophenyl trifluoroacetate, TFP-OTFA was prepared as previously described (24) . Sephadex LH-20 gel filtration resin was obtained from Fluka (Sigma-Aldrich, Milwaukee, WI). Melting points were obtained in open capillary tubes on a Mel-Temp II apparatus with a Fluke 51 K/J electronic thermometer, and are uncorrected.
Radioactive Materials
All radioactive materials were handled according to approved protocols at the University of Washington and Fred Hutchinson Cancer Research Center. Standard methods for safely using radioactive materials were employed (25) 111 In was conducted on a Capintec CRC-15R Radioisotope Calibrator using calibration numbers provided by the manufacturer. Samples containing 125 I or 111 In were counted in a Packard Cobra II gamma counter (PerkinElmer Life and Analytical Services, Waltham, MA). Radioactivity counts were imported into an Excel Spreadsheet (Microsoft Corp., Redmond, WA) where calculations of percent injected dose (%ID) and percent injected dose per gram (%ID/g) were made.
Spectral Analyses
1 H NMR spectra were obtained on a Bruker AV 500 (500 MHz) instrument. Proton chemical shifts are expressed as ppm using tetramethylsilane as an internal standard (δ = 0.0 ppm). Low-resolution mass spectral (LRMS) and high-resolution mass spectral (HRMS) data were obtained on a Bruker APEX III 47e Fourier Transform Mass Spectrometer using electrospray ionization. For analysis, the samples were dissolved in 50/50 MeOH/H 2 O and were introduced by an integral syringe infusion pump (Cole Parmer Series 74900).
Chromatography
All synthetic reactions were monitored by HPLC. Samples were assessed on a system that contained a Hewlett-Packard quaternary 1050 gradient pump, a variable wavelength UV detector (254 nm), and a Varex ELSD MKIII or an Alltech ELSD 2000 evaporative lightscattering detector. Analyses of HPLC data were conducted using Hewlett-Packard HPLC ChemStation software. Reversed-phase HPLC chromatography was carried out on an Alltech Altima C-18 column (5 µm, 250 × 4.5 mm) using a gradient solvent system at a flow rate of 1 mL/min. A gradient of MeOH and H 2 O/0.1% HOAc was used. Starting with 40% MeOH, the initial solvent mixture was held for 2 min, then the gradient was increased to 100% MeOH over the next 10 min, then held at 100% MeOH for 8 min. Retention times (t R ) under these conditions for compounds are provided with the compound experimental.
Some synthesized compounds were purified from crude reaction mixtures using a Biotage SP Flash Purification System (Charlottesville, VA) on a reversed-phase C18 FLASH 25+M column. The purification used a gradient mixture composed of MeOH and 0.1% aqueous HOAc solution (pH 3.25). The gradient started with 25% MeOH / 75% HOAc/H 2 O, and that mixture was held for 2 min. Following that, the % MeOH was increased linearly to 100% over the next 10 min, then held at 100% for 8 min. Fractions were collected based on UV detection at 215 or 254 nm. Fractions containing pure products were determined by analytical HPLC and were combined, solvent evaporated, and isolated to provide the yields listed.
The 111 In-labeling reactions of biotin derivatives 3a and 4a, to prepare [ 111 In]3b and [ 111 In]4b, were followed by radio-HPLC, and the products were purified by isolation from the HPLC effluent. The HPLC equipment used consisted of a Hewlett-Packard quaternary 1050 gradient pump, Waters 601 UV detector, and a Beckman model 170 radioisotope detector. Analysis of the HPLC data was conducted on Hewlett-Packard HPLC ChemStation software. The separations used a C-18 column (Altima C-18, 5 mm, 250 × 4.5 mm; Alltech, Deerfield, IL) with a gradient eluting at a flow rate of 1 mL/min. The gradient was composed of MeOH as solvent A and 0.1% HOAc in water as solvent B. The gradient started at 60% B, which was held for 2 min, then the percent of MeOH was increased linearly to 100% over the next 10 min. After reaching 100% MeOH, it was held at there for 8 min. This compound was prepared from aminoisophthalic acid, 5, by reaction with di-tert-butyl dicarbonate in basic DMF/H 2 O solution, followed by esterification with tetrafluorophenol and EDC in DMF as previously reported (21) .
To a solution of 2,2'-(ethylenedioxy)bis(ethylamine) (403 mL, 2760 mmol) in 200 mL of dichloromethane, di-tert-butyl dicarbonate (20 g, 91.6 mmol) with 200 mL of dichloromethane were added dropwise over 4 h. After the addition was completed, the reaction solution was allowed to stir at room temperature for 1 h. Dichloromethane was evaporated by rotoevaporator under vacuum, then the residue was dissolved in water (200 mL), washed with hexanes (2 × 200 mL). The aqueous solution was then extracted with dichloromethane (3 × 100 mL). The fractions of dichloromethane were combined and washed with water (3 × 100 mL), dried over anhydrous Na 2 SO 4 , then evaporated under vacuum on a rotoevaporator to yield 14.11 g (62%) of 7 as a colorless oil (used without further purification). 1 
2-(N-Biotinoyl)-L-aspartate-1-O-tert-butyl Ester, 11
This compound was prepared from biotin, 9, by reaction with 2,3,5,6-tetrafluorophenyl trifluoroacetate (TFP-OTFA) in an initial step, followed by reaction of the intermediate biotin tetrafluorophenyl ester with L-aspartic acid α-tert-butyl ester, 10, as previously reported (28).
4-(O-Tetrafluorophenyl)-2-(N-Biotinoyl)-L-aspartate-1-O-tert-butyl ester, 12
This compound was prepared by reaction of 11 with TFP-OTFA following a previously reported procedure (28) . 
Aminomethane-tris(N-(4,7,10-trioxa-13-amino)-N-(tert-butyloxycarbonyl)-3-propionylamine), 18
A 0.95 g (0.83 mmol) quantity of 17 was dissolved in 30 mL of absolute EtOH. To that solution was added 3g of a 50% RaNi/H 2 O slurry with stirring. The mixture was put under hydrogen (45 psi) and was stirred overnight. Hydrogen pressure dropped from 45 psi to 40 psi. Hydrogen was removed with a H 2 O aspirator vacuum and argon was introduced to the mixture, this procedure was repeated 3×, then the EtOH solution was filtered through a celite column. The solvent was removed from the filtrate to yield 0.95g (99%) of 18 as colorless oil. 1 
15-N-(Phthalimido)-(3,6,9,12-tetraoxa)pentadecanoic acid, 19
This compound was obtained from Quanta BioDesign (Powell, OH) and was used without further purification. 1 
1-(15-N-(Phthalimido)-(3,6,9,12-tetraoxa)pentadecanoylamino)methane-tris(N-(4,7,10-trioxa-13-amino)-N-(tert-butyloxycarbonyl)-3-propionylamine), 20
A 0.30 g (0.77 mmol) quantity of 19 was dissolved in 50 mL of anhydrous DMF. To that solution was added 0.89 g (0.77 mmol) of 18, 0.32 g (1.54 mmol) of DCC and catalytic amount of HOBT. This solution was stirred at room temperature over a weekend. Et 3 N was added to neutralize the residual TFA in the acid (from removal of tBu ester). When the acid and DCC were mixed a white precipitate was noted immediately. To purify, the solvent was removed under vacuum and the residue loaded onto a silicagel column and eluted with a gradient of 100% EtOAc to 50% MeOH/EtOAc to yield 0.85 g (72%) of 20 as a pale yellow oil. 1 
2,3,4,6-Tetra-O-acetyl-galactopyranosyl-1-β-pseudothiourea Hydrobromide, 23
This compound was prepared by reaction of 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide, 22, to form thiourea intermediate, 23, in a procedure similar to that previously described (29) . To a solution of 2.02 g (0.026 mol) of thiourea in 24 mL acetone was added 10 g (0.024 mol) of 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide, 22. The mixture was refluxed for 20 min, then cooled on ice. The solid was collected and rinsed with 10 mL of ice-cold acetone. The collected solid was suspended in 20 mL ice-cold acetone, then refluxed for 15 min, cooled on ice, and filtered. The solid was rinsed with 10 mL of ice-cold acetone, air dried, then dried under vacuum to yield 4.15 g (69%) of 23 as a colorless solid. This compound was used in the next step without further purification.
2,3,4,6-Tetra-O-acetyl-galactopyranosyl-1-β-(3'-thiopropionic acid), 24
This compound was prepared from the psuedothiourea intermediate, 23, as previously described (30) . Briefly, A mixture of 0.9 g (1.85 mmol) 23, 0.37 g (1.99 mmol) 3-iodopriopionic acid, 0.32 g (167 mmol) Na 2 S 2 O 5 and 0.30 g (2.15 mmol) potassium carbonate in 1.5 mL acetone / 1.5 mL H 2 O was stirred at room temperature for 45 min. To the mixture was added 7 mL of HCl (5%) and 7 mL of CHCl 3 . The CHCl 3 layer was separated, washed with H 2 O, dried with MgSO 4 , and evaporated to give 0.77 g (96%) of 24 as an oil. This compound was used in the next step without further purification.
2,3,4,6-Tetra-O-acetyl-galactopyranosyl-1-α-(3'-thiopropionate-O-2,3,5,6-tetrafluorophenyl ester), 25
To a solution of 24 (772 mg, 1.77mmol) in anhydrous DMF (15mL) at 0°C, was added dropwise TFP-OTFA (0.448 mL, 2.6 mmol), followed by addition of Et 3 N (0.362 mL, 2.6 mmol). The mixture was stirred in an ice-bath for 1 h. 
N-(15-(N,N'-Bis(N-(biotinyl)-β-N-(tert-butyloxycarbonyl)-N-(8-amino-3,6-dioxaoctanyl)aspartamidyl)-5-aminoisophthalamido)-(3,6,9,12-tetraoxa)pentadecanoylamino)methane-tris(N-(4,7,10-trioxa-13-amino)-3-propionylamine), 28
A 139 mg (0.052 mmol) quantity of 27 was stirred in 2 mL of TFA for 45 min. The excess TFA was removed under a stream of air. The residue was washed with diethyl ether and was placed under high vacuum overnight. The crude residue was dissolved in H 2 O and was purified over a Sephadex LH-20 gel filtration column to yield 92.8 mg (0.036 mmol; 69%) of 28. This compound was used in the next step without further characterization. N,N'-Bis(N-biotinyl-N-(8-amino-3,6-dioxaoctanyl)aspartamidyl-5-N- The radiolabeling reactions were conducted with metal free reagents and labware. Methods for demetallation have been previously described (31 
Avidin Bead Assay
The avidin beads were prepared for use by the following procedure. A solution of avidinagarose from the manufacturer (Sigma-Aldrich #A9207-5 mL or ImmunoPure Immobilized Avidin Gel, Pierce Biotechnology, Inc. Rockford, IL) was vortexed, and then a 300 µL aliquot of the suspended avidin-agarose beads was added to a microcentrifuge filter (Fisher #07-200-387; 0.45 mm cellulose acetate spin column with centrifuge tube filter). The filter was placed in a microcentrifuge and spun at 1000g for 1 min. The filtrate was discarded.
The binding assay was conducted as follows. A 300 µL aliquot of PBS was added to filter (with avidin-agarose) and vortexed to thoroughly mix. The beads were spun at 1000g for 1 min, and then the PBS filtrate was discarded. The PBS washing step was repeated, then an aliquot (up to 2 µL) of 111 In-labeled biotin ([ 111 In]3b or [ 111 In]4b) was added to the suspended beads, and this suspension was vortexed to mix thoroughly. The 111 In-labeled biotin was incubated with the beads for 10 min at room temperature. The mixture was vortexed to mix, then placed in microcentrifuge and spun at 1000g for 1 min. The filtrate was set aside, and 300 µL of PBS was added to the avidin-agarose beads as a wash. The filter was vortexed to mix, then was placed in a microcentrifuge and spun at 1000g for 1 min. The filtrate was combined with the previous filtrate. The microcentrifuge filter containing avidin-agarose beads was placed in a tube, then that tube and the tube containing the combined filtrates were counted in a gamma. The quantity of 111 In-labeled biotin derivative remaining in the filter (% bound) was calculated as [radioactivity in filter]/ [radioactivity in filter]+[radioactivity in filtrates]*100.
Lymphoma cell line
The human Ramos B lymphoma cell line (American Type Culture Collection, Bethesda, MD) was maintained in log-phase growth in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum in a 5% CO 2 incubator.
Synthesis and purification of anti-CD20 1F5 scFv 4 -SAv fusion proteins
The production and purification of 1F5 scFv 4 -SAv-WT fusion protein and the related sitedirected SAv mutant fusion proteins, 1F5 scFv 4 -SAv-S45A and 1F5 scFv 4 -SAv-Y43A, have been previously described (17, 18) . Briefly, scFv-SAv fusion genes were produced by molecularly fusing the single-chain variable regions (scFv) of the murine anti-CD20 1F5 antibody to either the full length SAv wild-type gene or SAv mutant genes. The resultant fusion proteins were expressed in the periplasmic space of E. coli and spontaneously formed stable soluble tetramers of 1F5 scFv 4 -SAv with a molecular weight of 174 kDa. The 1F5-SAv fusion proteins were formulated at a concentration of 3 mg/mL in phosphate buffer saline (PBS) containing 5% sorbitol.
Preparation of 1F5 [ 125 I]scFv 4 -SAv-S45A fusion protein
Fusion proteins were radioiodinated with Na[ 125 I]I (PerkinElmer, Waltham, MA) by the chloramine-T method in a manner similar to that previously published (32) . Briefly, 50 µL of a 1 mg/mL solution of chloramine-T (Sigma-Aldrich, St. Louis, MO) was added to 500 µL fusion protein. Next the Na[ 125 I]I was added and the solution vortexed. Following a 1 minute incubation at room temperature, 5 µL of a 1 mg/mL solution of sodium metabisulfite was added and the solution was vortexed. The contents were pipetted onto a pre-washed PD10 column, eluted with PBS, collecting 600 µL fractions. The amount of radioactivity in each fraction was measured in a Capintec CRC-7 Radioisotope Calibrator, and early fractions with the highest activity were pooled to obtain the labeled fusion protein. 
RESULTS

Synthesis of the blood clearance agent, 2
The synthesis of 2 utilized a convergent approach, combining a bis-biotin component, a tetrafunctional polyethylene glycol (PEG) component, and a galactosyl component. The syntheses of the individual components are shown in Schemes 1 -3. The synthetic steps to prepare the bis-biotin derivative 13 are shown in Scheme 1. In the synthesis, aminoisophthalic acid, 5, was modified with di-tert-butyl-dicarbonate, then tetrafluorophenol and EDC were used to prepare N-Boc-aminoisophthalate ditetrafluorophenyl ester, 6. Reaction of 6 with mono-Boc protected diamino-dioxaoctane, 7, and triethylamine in anhydrous DMF provided the tri-N-Boc protected aminoisophthalic acid derivative, 8. After removal of the N-Boc groups on 8 with neat TFA, the resulting alkyl amines were reacted with the tetrafluorophenyl ester of the biotin-aspartate adduct 12, which was prepared from biotin, 9, as previously described (28) . That reaction provided the anilino-bis-biotin derivative 13 in 74% yield. It should be noted that the synthesis was conducted in this manner so that the aspartate carboxylates remained as tert-butyl esters in bis-biotin derivative 13, since that is required to prepare the isocyanate functionality in a later step of the synthesis.
A key part of the design of the blood-clearing agent 2 was the inclusion of three galactosyl groups at the terminus of polyethylene glycol (PEG) spacer arms. A PEG-containing tetra-functional molecule, 21, was utilized as a core for the branched galactosyl portion of 2. In the final step, the acetyl protecting groups were removed from 29 using an acid form of an ion exchange column to provide a 94% yield of the targeted blood clearance agent 2.
Syntheses of the bis-biotin-DOTA derivative, 4a
Partial synthesis of the radiometal-binding bis-biotin derivative 4a is shown in Scheme 5. The initial steps of the synthesis involved preparation of bis-biotin derivative 13, as described previously (and shown in Scheme 1). Conversion of the aniline in 13 to the phenylisothiocyanate functionality in 30 was accomplished by reaction with thiocarbonyldiimidazole (TCDI). The isothiocyanate derivative, 30, was prepared and used in this coupling reaction, rather than the phenylisocyanate, 26, due to the low reactivity of the aniline. Reaction of 30 with aminobenzylDOTA, 31, using pyridine as the base, provided the adduct 32 in 75% yield. Removal of the tert-butyl esters in 32 was accomplished in neat TFA to provide the bis-DOTA-biotin compound 4a in 95% yield.
Radiolabeling
The 1F5 scFv 4 -SAv-S45A mutant fusion protein was radioiodinated in a standard protocol using chloramine-T as the oxidant. Several 111 In-labeling reactions of the biotin derivative 3a conducted for these studies provided isolated radiochemical yields (72-95%) of [ 111 In]3b, with radiochemical purities of 95-99% being obtained as measured in an avidin binding assay. It should be noted that the labeling yields reported are for the isolated product, and in some examples not all of the [ 111 In]3b was isolated from the HPLC eluant making the radiolabeling yields appear lower. In labeling optimization studies, radiolabeling yields of 97+% were obtained for [ 111 In]3b under a variety of reaction conditions studied.
Radiolabeling reactions of 4a with 111 In were more variable, providing ranges of isolated radiochemical yields from 45% to 94% under the reaction conditions used. The radiolabeled product was purified by radio-HPLC. Analysis of the radiochemical purity of [ 111 In]4b, as determined by the avidin bead assay, was 85-95% for the preparations (some were HPLC purified). In subsequent labeling optimization studies, it was found that consistently high 111 In-labeling yields (90+%) could be obtained for the reaction of 4a by conducting the reactions in 0.5 M ammonium acetate buffer at pH 5.3 and lowering the reaction temperature to 45°C (from 85°C).
Comparison of blood clearance with 1 and 2
An experiment was conducted to determine the effectiveness of 1 and 2 for decreasing 1F5 scFv 4 -SAv-S45A mutant fusion protein concentration in blood. In the experiment, the blood concentrations were assessed in three groups of four athymic FoxN1 Nu mice after administration of 1F5 [ 125 I]scFv 4 -SAv-S45A. Serial blood samples were obtained and counted to assess the blood concentrations. A logarithmic plot of the blood concentrations of 1F5 [ 125 I]scFv 4 SA-S45A in the three groups of mice, as a function of time, is provided in Figure 2 (data is provided as Table S1 in Supporting Information). could be used in a pretargeting protocol to effectively target tumor xenografts in the presence of endogenous biotin. The biodistribution study did not include groups of mice on biotin-deficient diets when scFv 4 -SAv mutant fusion proteins were administered, as no difference in tumor concentrations were seen previously in pretargeting experiments using the same fusion proteins in mice placed on biotin-deficient diets or standard diets (22) .
In the pretargeting experiment, four groups of female FoxN1 NU athymic nude mice (5 mice/ group) bearing Ramos lymphoma xenografts were administered the fusion proteins (FP), blood clearance agents (CA) and radiolabeled biotin derivatives (RB) as depicted in Scheme 6. Group 1 was fed a biotin-deficient diet and groups 2 through 4 were fed standard diets. Twenty hours after anti-CD20 fusion protein administration, the mice received a blood clearing agent, either 1 or 2, followed 4 hours later by either [ 111 , and selected tissues were harvested. The tissues were counted in a gamma counter, and the concentration of 111 In in each tissue was calculated as %ID/g. A bar graph showing the concentrations in tumor xenografts and selected tissues is provided as Figure 3 (data is provided as Table S2 in Supporting Information). An additional biodistribution study was conducted in athymic mice injecting [ 111 In]4b alone. In that biodistribution, the only tissue that had more than 1% ID/g was kidney (1.57 ± 0.10, 1.54 ± 0.11 and 1.03 ± 0.20 at 1, 4 and 24 h pirespectively), and most tissue concentrations were less than 0.2 %ID/g (Table S3 in Supporting Information). Figure 3 shows the dramatic effect that endogenous biotin can have on tumor concentrations of radiolabeled biotin in pretargeting protocols. were of a similar magnitude for the three fusion proteins, except in the blood and liver. The blood concentrations in the groups administered SAv mutant fusion proteins, scFv 4 -SAv-S45A and scFv 4 -SAv-Y43A, were much higher (0.18 ± 0.06 %ID/g and 0.58 ± 0.13 %ID/g) than in the groups administered scFv4-SAv-WT (0.008 ± 0.002 %ID/g and 0.004 ± 0.001 %ID/g), indicating that CA 2 was less efficient at clearing the SAv mutant fusion proteins than CA 1 was with the SAv WT fusion protein.
Similarly, liver concentrations in the groups administered SAv mutant fusion proteins, scFv 4 -SAv-S45A and scFv 4 -SAv-Y43A, were somewhat higher (1.77 ± 0.4% ID/g and 3.99 ± 0.8% ID/g, respectively) than were obtained in groups administered the scFv 4 -SAv-WT fusion protein (0.43 ± 0.1% ID/g and 0.36 ± 0.18 %ID/g).
DISCUSSION
The ultimate goal of our studies is to develop a pretargeting protocol based on the streptavidin/biotin binding pair that provides good tumor targeting of therapeutic radionuclides in the presence of endogenous biotin, while having minimal localization of the radionuclides in normal tissues. Although endogenous biotin has not precluded the use of antibody-streptavidin conjugates or fusion proteins in clinical studies (33) , it has the potential to significantly diminish the blood clearance and tumor targeting of the radiolabeled biotin derivatives in patients. In the pretargeting approach being investigated, a recombinant tetrameric fusion protein, combining the scFv portion of the anti-CD20 antibody 1F5 with streptavidin mutants that have decreased binding for biotin, is used in combination with a bis-biotin derivative that is radiolabeled with a diagnostic or therapeutic radionuclide. Due to its bivalency, bis-biotin derivatives have higher binding avidities than biotin, allowing their preferential binding with SAv mutants in the presence of endogenous biotin. The SAv mutants used in this investigation have a serine or tyrosine in the biotinbinding pocket replaced with an alanine residue (S45A and Y43A, respectively, (17)). In initial proof-of-principle studies, the SAv-Y43A mutant was found to have a 67-fold lower affinity for biotin than the wild-type (WT) SAv, and the off-rate for the bis-biotin was found to be 640 times slower than biotin when binding SAv-Y43A (21) . This combination of reagents was previously found to target radionuclides to lymphoma xenografts in the presence of endogenous biotin, but normal tissues had significant concentrations of the radionuclides (22) . Thus, the primary goal of this investigation was to design and synthesize a galactose-containing bis-biotin reagent that would bind in vivo with a scFv 4 -SAv fusion protein, such that more efficient blood clearance of the fusion proteins could be attained. In addition to preparation of an effective clearing agent, a bis-biotin derivative that could be radiolabeled with 111 In and 90 Y was prepared such that those radiometals could be used in the pretargeting protocols with mutant SAv fusion proteins.
The majority of our pretargeting investigations have used the biotin-hexadecylgalactosamine reagent, 1 (also referred to as N-acetylgalactosamine-biotin or NAGB)4, to affect clearance of the wild-type SAv conjugates of, or fusion proteins with, antibodies. The asialoglycoprotein receptors, also referred to as Ashwell receptors, are hepatic plasma membrane receptors responsible for regulating the concentrations of circulating glycoproteins (34, 35) . This regulation is controlled by removal of sialic acid termini on glycoproteins to expose terminal galactose residues, allowing binding with the asialoglycoprotein receptor. It has been shown that asialogycoproteins are bound to liver membranes by a saturable, calcium dependent process. Bis-biotin blood-clearance reagent 2 was designed to bind with SAv in antibody conjugates or fusion proteins in the blood, then bind with the asialoglycoprotein receptors in the liver to clear them from blood. The studies also demonstrated that a 9-atom linker between the sugar and protein provided a higher RIP then when there was a 2 or 5 atom linker. Those early studies set a basis for the use of galactosyl conjugates for removal of proteins from blood using the asialoglycoprotein receptors, and began to define some of the structural requirements of the conjugates for efficient binding.
The difficulty in synthesizing a bis-biotin counterpart to the large clearing agent 1 led us to consider whether the 16 galactosyl moieties were required for effective blood clearance. There are literature reports suggesting that as few as three galactosyl moieties may be effective. In early studies, Lee recognized that a number of biological systems require clustering of glycosides for biological activity, and that such clustering was often obtained from branched structures, so he prepared a number of tri-glucose and tri-galactose derivatives for study (37) . Evaluation of mono-, bis-, and tris-galactosyl derivatized bovine serum albumin binding with rabbit liver membrane demonstrated that the tris-galactosyl conjugates were better at inhibiting binding of [ 125 I]ASOR than the bis-galactose conjugate, which was better than the mono-galactose conjugate (38) . In another study, Lee et al. demonstrated that the number of branched galactose moieties provided dramatic differences in inhibitory potency, with tetra-> tris->bis->mono (39) . The 50% inhibitory value was ~ 1 mM for the mono-galactose conjugate, whereas it was ~1 nM for the tri-galactose conjugate. This large difference in binding inhibition based on the number of galactose residue in branched chains was also noted by Bezouska et al. (40) . It was noted by Baenziger and Maynard that the galactose residues may bind two sites simultaneously, and speculated that the sites might be 25-30Å apart (41) . In a later study, Lee et al. synthesized "cluster ligands" with 1, 2, 3, 4 or 6 terminal galactose moieties (42) . They found that the highest binding was obtained with the highest number of galactose moieties (i.e. 6 moieties), but that the binding affinity increased only a modest amount for the compounds containing 4 or 6 galactose moieties relative to the high binding of the compound that had 3 galactose moieties in a "flexible" structure. (43) . They found that the binding affinity of the tri-galactose cluster compounds was strongly correlated with the length of the spacer between the galactosyl residues and the branching point of the galactoside, with a factor of 2000× higher affinity with the 20Å spacer vs. the 4Å spacer.
The information from the literature provided the basis for the structure of galactosecontaining portion of 2. Our previous studies demonstrating successful in vivo targeting of tumor xenografts with a radioiodinated bis-biotin derivative led us to retain the main structural features of that portion of the compound. Those structural features included; (1) appropriate functional groups to provide a distance between biotin carboxyate carbonyl functionalities of ~40Å, (2) carboxylate groups on the carbon alpha to the biotinamide functionalities, (3) diamino-dioxaoctane spacer arms to increase aqueous solubility of compound. The distance between biotin moieties was chosen as the distance that was adequate to readily bind the two biotin-binding pockets on one face of the streptavidin mutants (19) . The addition of the carboxylates alpha to the biotinamide provided protection from in vivo cleavage of the biotinamide bonds by the enzyme biotinidase (28) . The structural properties that were previously shown to bind asialoglycoprotein receptors in liver were combined with the bis-biotin structural properties desired for binding with streptavidin mutants to design blood clearance agent 2. A blood clearance study demonstrated that the fusion protein 1F5 [ 125 I]scFv4-S45A could be more efficiently cleared from blood in mice after administration of 2 than when 1 was administered. This is shown in Figure 2 . Importantly, use of 2 in a pretargeting study, where both 1F5 scFv4-SAv-S45A and 1F5 scFv4-SAv-Y43A fusion proteins (in separate groups) were evaluated with bis-biotin [ 111 In]4b, resulted in normal tissue concentrations that were much lower than obtained in our previous pretargeting studies employing those fusion proteins with CA 1 and a radioiodinated bis-biotin derivative. The tissue concentration data obtained in the pretargeting study are shown as a bar graph in Figure 3 . The most striking differences between [ 111 In]4b and [ 111 In]3b concentrations in tissues were found in the blood and liver. The higher blood concentrations are most likely brought about by less efficient blood clearance using 2, however, it is unclear why the liver concentrations of [ 111 In]4b are somewhat higher. There may be several possible contributing factors to the observed differences in liver concentrations. For example, a contributing factor may be the difference in the nature of the galactose derivative in the clearing agents, 1 and 2. In 1 the galactose derivative is an N-acetyl-galactosamine moiety, whereas in 2 it is a galactose moiety. Although most literature relating to developing ligands for binding to asialoglycoprotein receptor are directed at galactose derivatives, it has been reported that the avidity of agents with terminal N-acetylgalactosamine moieties is greater than those terminated with galactose moieties (41) . Indeed, studies have shown that tris-N-acetyl-Dgalactosamine derivatives can have subnanomolar binding with the asialoglycoprotein receptor (45) . Another possible contributing factor is higher denticity (i.e. more galactosamine residues), which could increase the rate of cell internalization (20) . Yet another possible contributing factor is the binding avidity of the bis-biotin with the mutant fusion protein. It seems likely that the difference in binding of 1 with the mutant proteins contributes to the higher liver concentrations, as the liver concentration of [ 111 In]4b at the time of sacrifice was about 2× higher when the fusion protein 1F5 scFv 4 -SAv-Y43A was used than when 1F5 scFv 4 -SAv-S45A was used. It is not possible to determine the reason for the differences in liver concentrations with the data obtained, particularly with the complexity of the internalization process (46) and receptor/ligand recycling that has been observed (47, 48) . Further studies need to be conducted to understand which parameters affect the observed higher liver concentrations.
In conclusion, the pretargeting approach using a combination of SAv mutant fusion proteins, bis-biotin-trigalactose blood clearance agent 2, and 111 In-labeled DOTA-bis-biotin, [ 111 In]4b, was found to target lymphoma tumor xenografts in high concentrations, resulting in far superior biodistributions compared with the 1F5 scFv 4 -SAv-WT conjugate system in the presence of endogenous biotin. While the new blood clearance agent, 2, has been shown to greatly decrease the radioactivity concentrations in most normal tissues relative to CA 1, the fact that higher blood and liver concentrations were obtained indicates that the structure of 2 is not optimal. Optimization of the structure of 2 might include use of Nacetylgalactosamine residues in the place of galactose residues, and incorporation of higher number of galactosamine residues (i.e. [4] [5] [6] . While CA 2 is not optimized, we believe the results obtained are adequate to support investigation of 2 and 4a in pretargeting therapy studies using scFv 4 -SAv mutant fusion proteins in tumor-bearing mice fed standard diets.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Graph (log scale) of 1F5 [ 125 I]scFv 4 -SAv-S45A fusion protein concentration (%ID/g) when no blood clearance agent was used (group 1; red line), or after administration of one of the biotinyl-galactosyl-blood clearance agents, 1 (group 2, blue line) or 2 (group 3, green line). In the experiment, three groups of athymic FoxN1 Nu mice (n = 4 per group) were injected intravenously at t = 0 with 2.8 nmol of 1F5 [ 125 I]scFv 4 -SAv-S45A fusion protein, followed 24 hours later with an intravenous injection of 5.8 nmol of either 1 or 2. Serial blood samples were obtained from the tail vein and 125 I was counted in a gamma counter. The %ID/g was calculated based on separately counted injection standards. Average %ID/g values are plotted with error bars representing ± standard deviation. The plotted data are provided as Table S1 in Supporting Information.
Scheme 6.
Schematic depicting the time course of reagent injections (panel A) and the reagents used in each study group (panel B) in the pretargeting experiment.a a In the experiment, the reagents outlined in the table (panel B) were administered to 4 groups of mice (n = 5/group) following the timeline shown (panel A). The fusion protein (FP) was initially injected (t = 0 h), followed 20 hours later by a clearing agent (CA, 1 or 2). Four hours later, the radiolabeled biotin (RB) derivative, [ 111 In]3b or [ 111 In]4b, was administered. Mice were sacrificed at 48 hours post the fusion protein. Tumor xenografts and selected tissues were harvested and counted to determine concentrations (%ID/g) of 111 In-labeled biotin derivative in the tissues.
